Funds holding HCW BIOLOGICS INC
ISIN US40423R2040 · United States · LEI 5299008ZJ4RXXTN04Z97
- Fund holders
- 6
- Of which ETFs
- 0 6 other funds
- Value held
- ≈ 30.5K $ 11.3K $ · 16.4K €
- Share of capital
- 1.4 % of 1.8M shares on Aug 12, 2026
| Fund | Shares | Value | Weight in fund | Share of capital | |
|---|---|---|---|---|---|
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 12,023 | 4.3K $ | 0.65 % | as of Mar 31, 2026 ↗ | |
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 10,180 | 5.5K $ | 0.55 % | as of Feb 28, 2026 ↗ | |
| Fidelity Series Total Market Index Fund Fidelity Concord Street Trust | 1,488 | 804.4 $ | 0.08 % | as of Feb 28, 2026 ↗ | |
| Fidelity Total Market Index Fund Fidelity Concord Street Trust | 726 | 392.5 $ | 0.04 % | as of Feb 28, 2026 ↗ | |
| Fidelity Nasdaq Composite Index Fund Fidelity Concord Street Trust | 412 | 222.7 $ | 0.02 % | as of Feb 28, 2026 ↗ | |
| ABANTE QUANT VALUE, F.I. ABANTE ASESORES GESTION, SGIIC, S.A. | 16.4K € | 0.09 % | as of Dec 31, 2025 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| ABANTE QUANT VALUE, F.I. ABANTE ASESORES GESTION, SGIIC, S.A. | 0.09 % | as of Dec 31, 2025 ↗ |
Quarter after quarter
Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.
| Quarter | Holders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q2 | 5 | 0 | 24,829 | +13.3 % |
| 2026Q1 | 5 | 0 | 21,914 | +2.3 % |
| 2025Q4 | 5 | 0 | 21,413 | +74.7 % |
| 2025Q3 | 5 | 12,260 |
Institutional managers
12 managers declare this company to the SEC (Form 13F).
| Manager | Shares | Value | |
|---|---|---|---|
| HRT FINANCIAL LP | 266,393 | 95 $ | as of Mar 31, 2026 |
| Virtu Financial LLC | 47,809 | 17 $ | as of Mar 31, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | 35,886 | 12.9K $ | as of Mar 31, 2026 |
| CITADEL ADVISORS LLC | 26,083 | 9.4K $ | as of Mar 31, 2026 |
| Tower Research Capital LLC (TRC) | 14,839 | 5.3K $ | as of Mar 31, 2026 |
| JANE STREET GROUP, LLC | 14,134 | 5.1K $ | as of Mar 31, 2026 |
| CITIGROUP INC | 10,528 | 3.8K $ | as of Mar 31, 2026 |
| Golden State Wealth Management, LLC | 10,000 | 3.6K $ | as of Mar 31, 2026 |
| UBS Group AG | 9,221 | 3.3K $ | as of Mar 31, 2026 |
| WELLS FARGO & COMPANY/MN | 1,000 | 360 $ | as of Mar 31, 2026 |
| OSAIC HOLDINGS, INC. | 26 | 9 $ | as of Mar 31, 2026 |
| NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 2 | 1 $ | as of Mar 31, 2026 |
Declared shareholders of HCW BIOLOGICS INC
There is 1 beneficial ownership filing. These stakes do not add up. An asset manager that files includes its own funds, which already appear among the funds on this page.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| Armistice Capital, LLC and 1 other | 4.99 % | 353,680 | as of Mar 31, 2026 · SCHEDULE 13G |
Cite this page
Titelia. "Funds holding HCW BIOLOGICS INC". https://titelia.com/en/stocks/hcw-biologics-inc-US40423R2040